NMD670 is a first-in-class small molecule inhibitor of skeletal muscle-specific chloride channel (ClC-1) with an EC50 of 1.6 μM. It improves muscle weakness and fatigue in neuromuscular diseases and may serve as a potential therapeutic approach for Myasthenia Gravis (MG).